Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
Authors
Keywords
-
Journal
Nature Communications
Volume 7, Issue -, Pages 10501
Publisher
Springer Nature
Online
2016-02-17
DOI
10.1038/ncomms10501
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial
- (2015) Naiyer A Rizvi et al. LANCET ONCOLOGY
- Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
- (2015) Edward B. Garon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- limma powers differential expression analyses for RNA-sequencing and microarray studies
- (2015) Matthew E. Ritchie et al. NUCLEIC ACIDS RESEARCH
- B7-H1/PD-1 Blockade Therapy in Non–Small Cell Lung Cancer
- (2014) Scott Gettinger et al. CANCER JOURNAL
- Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy
- (2014) J. M. Taube et al. CLINICAL CANCER RESEARCH
- PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
- (2014) Alena Gros et al. JOURNAL OF CLINICAL INVESTIGATION
- Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
- (2014) Matthew M. Gubin et al. NATURE
- CEACAM1 regulates TIM-3-mediated tolerance and exhaustion
- (2014) Yu-Hwa Huang et al. NATURE
- MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
- (2014) Thomas Powles et al. NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Tim-3: An Emerging Target in the Cancer Immunotherapy Landscape
- (2014) A. C. Anderson Cancer Immunology Research
- The Impact of Genomic Changes on Treatment of Lung Cancer
- (2013) Stephanie Cardarella et al. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE
- Immune Modulation in Cancer with Antibodies
- (2013) David B. Page et al. Annual Review of Medicine
- Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease
- (2013) Kadoaki Ohashi et al. JOURNAL OF CLINICAL ONCOLOGY
- Acquired Resistance to Crizotinib from a Mutation in CD74–ROS1
- (2013) Mark M. Awad et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors
- (2013) E. A. Akbay et al. Cancer Discovery
- TIM3+FOXP3+regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer
- (2013) Kaori Sakuishi et al. OncoImmunology
- Radiotherapy Increases the Permissiveness of Established Mammary Tumors to Rejection by Immunomodulatory Antibodies
- (2012) I. Verbrugge et al. CANCER RESEARCH
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia
- (2011) Q. Zhou et al. BLOOD
- Anti-TIM3 Antibody Promotes T Cell IFN- -Mediated Antitumor Immunity and Suppresses Established Tumors
- (2011) S. F. Ngiow et al. CANCER RESEARCH
- Dysregulation of TIM-3-Galectin-9 Pathway in the Cystic Fibrosis Airways
- (2011) I. Vega-Carrascal et al. JOURNAL OF IMMUNOLOGY
- Emerging Tim-3 functions in antimicrobial and tumor immunity
- (2011) Kaori Sakuishi et al. TRENDS IN IMMUNOLOGY
- Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
- (2010) Kaori Sakuishi et al. JOURNAL OF EXPERIMENTAL MEDICINE
- T Cell/Transmembrane, Ig, and Mucin-3 Allelic Variants Differentially Recognize Phosphatidylserine and Mediate Phagocytosis of Apoptotic Cells
- (2010) Rosemarie H. DeKruyff et al. JOURNAL OF IMMUNOLOGY
- Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation
- (2010) Cole Trapnell et al. NATURE BIOTECHNOLOGY
- Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection
- (2010) H.-T. Jin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- (2008) Jeffrey A Engelman et al. NATURE MEDICINE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now